121 related articles for article (PubMed ID: 35971857)
1. Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Palumbo C; Dalla Volta A; Zamboni S; Mazziotti G; Zamparini M; Triggiani L; Borghetti P; Maffezzoni F; Bresciani R; Rinaudo L; Valcamonico F; Farina D; Magrini SM; Antonelli A; Simeone C; Berruti A
J Clin Endocrinol Metab; 2022 Nov; 107(12):3398-3407. PubMed ID: 35971857
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A; Palumbo C; Zamboni S; Mazziotti G; Triggiani L; Zamparini M; Maffezzoni F; Rinaudo L; Bergamini M; Di Meo N; Caramella I; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Berruti A
J Endocrinol Invest; 2024 Feb; 47(2):335-343. PubMed ID: 37458931
[TBL] [Abstract][Full Text] [Related]
3. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
[TBL] [Abstract][Full Text] [Related]
4. Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.
Palumbo C; Antonelli A; Triggiani L; Dalla Volta A; Maffezzoni F; Zamboni S; Borghetti P; Rinaudo L; Valcamonico F; Maroldi R; Magrini SM; Simeone C; Berruti A;
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):852-859. PubMed ID: 33723362
[TBL] [Abstract][Full Text] [Related]
5. Correlation between salivary and serum markers of bone turnover in osteopenic rats.
Pellegrini GG; Gonzales CM; Somoza JC; Friedman SM; Zeni SN
J Periodontol; 2008 Jan; 79(1):158-65. PubMed ID: 18166106
[TBL] [Abstract][Full Text] [Related]
6. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
7. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
8. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
9. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.
Stoch SA; Parker RA; Chen L; Bubley G; Ko YJ; Vincelette A; Greenspan SL
J Clin Endocrinol Metab; 2001 Jun; 86(6):2787-91. PubMed ID: 11397888
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
[TBL] [Abstract][Full Text] [Related]
11. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
12. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
13. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
14. Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials.
Zibellini J; Seimon RV; Lee CM; Gibson AA; Hsu MS; Shapses SA; Nguyen TV; Sainsbury A
J Bone Miner Res; 2015 Dec; 30(12):2168-78. PubMed ID: 26012544
[TBL] [Abstract][Full Text] [Related]
15. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
[TBL] [Abstract][Full Text] [Related]
16. Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Yu EY; Kuo KF; Gulati R; Chen S; Gambol TE; Hall SP; Jiang PY; Pitzel P; Higano CS
J Clin Oncol; 2012 May; 30(15):1864-70. PubMed ID: 22493411
[TBL] [Abstract][Full Text] [Related]
17. [PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS].
Ren H; Shen G; Jiang X; Liang D; Tang J; Cui J; Lin S; Zhuang H; Yang Z; Zhang S; Yao Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2015 Mar; 29(3):307-14. PubMed ID: 26455196
[TBL] [Abstract][Full Text] [Related]
18. Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis.
Kundaktepe BP; Sozer V; Kundaktepe FO; Durmus S; Papila C; Uzun H; Simsek G; Gelisgen R
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577803
[No Abstract] [Full Text] [Related]
19. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
20. Relationships between muscle mass, strength and regional bone mineral density in young men.
Sutter T; Toumi H; Valery A; El Hage R; Pinti A; Lespessailles E
PLoS One; 2019; 14(3):e0213681. PubMed ID: 30849119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
